Tea catechins exhibit a broad range of pharmacological activities that impart beneficial effects on human health. Epigallocatechin-3-gallate (EGCG), a primary component of tea catechins, has been widely associated with cancer prevention and treatment. In addition, tea catechins in combination with anticancer drugs are being evaluated as a new cancer treatment strategy. However, the interactions of anticancer drugs with tea catechins are largely unknown. Accumulated data indicate significant interactions between anticancer drugs and tea catechins, such as synergistic tumor inhibition or antagonist activity. Therefore, it is critical to understand comprehensively the effects of tea catechins on anticancer drugs. Focusing on evidence from preclinical studies, this paper will review the interactions between anticancer drugs and tea catechins, including pharmacodynamics and pharmacokinetics effects. We hope that by detailing the interactions between anticancer drugs and tea catechins, more attention will be directed to this important therapeutic combination in the future.
Introduction
Tea is an aromatic beverage made from the leaves of the plant Camellia sinesis Theaceae. Tea has been used for thousands of years in Asia, and it has transitioned from a medicinal herb to a consumed beverage. Now, tea is popular throughout the world [1] , as it is the most widely consumed beverage, being second only to water.
During the last 30 years, tea production increased by 148% from 1838 thousand tons in 1981 to 4563 thousand tons in 2011 (Fig. 1) . The majority of the tea-producing countries are located in Asia and Africa. China, India, Sri Lanka, Kenya and Indonesia are the major producers, account for 77% of the world's production and 80% of global exports. Depending on the manufacturing process, teas can be categorized into three major groups, green tea (non-fermented), black tea (fermented), and oolong tea (semi-fermented) [1, 2] .
Green tea constitutes approximately 20% of the world's tea production. In addition to being a popular beverage, the pharmacological effects of green tea have been studied extensively, resulting in a significant increase in the number of scientific publications in the last 30 years (Fig. 2 ). For example, numerous studies have shown that green tea possesses anti-cancer [3] , anti-oxidative [4] , anti-viral [5] , anti-bacterial [6] , cancer prevention [7, 8] , hypolipidemic [9] , anti-inflammatory [10] and hypotensive activities [11] . These remarkable health benefits are inseparable from a large number of bioactive compounds found in tea production. When green tea is brewed in hot or boiling water, it is comprised of 1/3 water-extractable materials, including polyphenols, caffeine, heobromine, theophylline and phenolic acids [1, 2, 12] . As shown in Fig. 2 , more papers have been published on tea catechins than tea caffeine. Polyphenols (generally known as catechins) are the major constituents of green tea, accounting for approximately 1/3 of the compounds found in green tea [1, 2] . The major catechins in green tea are (-)-epigallocatechin-3-gallate (EGCG),
(-)-epicatechin (EC), (-)-epicatechin-3-gallate (ECG) and (-)-epigallocatechin (EGC).
( Fig. 3) A total of 146 clinical trials involving green tea are listed in ClinicalTrials.gov (http://clinicaltrials.gov/). As shown in Fig. 4 , most of these studies are in cancer (31% of therapeutics analyzed). The cancer prevention and treatment activities resulting from tea consumption have been widely studied and discussed in several review articles [7, [13] [14] [15] [16] . In 1993, Yang et al. reported the first comprehensive review of the cancer-preventive activities of tea [17] . In recent decades, numerous laboratory studies in different animal models suggest that tea (mainly green tea) and tea constituents inhibit carcinogenesis [18] . Research in cell lines has also demonstrated that tea catechins can affect a range of signaling and metabolic pathways, subsequently resulting in cancer cell growth inhibition and apoptosis as well as inhibition of invasion, angiogenesis and metastasis [19] . In addition, epidemiological studies suggest that increased intake of green tea offers protective effects against the development of cancer at several human organ sites, particularly the upper gastrointestinal tract, lung and hepatocellular cancers [7, 14] .
Currently, an increasing number of cancer patients consume tea concomitantly with chemotherapeutics agents. However, tea may affect the pharmacokinetics and pharmacodynamics of chemotherapeutic agents, causing tea-drug interactions.
Unfortunately, clinicians and consumers do not always have information regarding the interactions between tea constituents and chemotherapeutics agents. This article highlights data on the interactions of tea with chemotherapeutics agents by focusing on pharmacodynamics and pharmacokinetics. An additional goal is to make recommendations to encourage additional clinical trials investigating tea and anticancer agents.
The synergistic effects of green tea with anticancer drugs in xenograft mouse models
Numerous laboratory studies have demonstrated that green tea or catechins display synergistic tumor growth inhibition with chemotherapeutics agents [20] [21] [22] [23] [24] . For example, in various animal tumor models, tea catechins (especially EGCG) inhibit tumor formation in mice and enhance the growth inhibition of xenografted tumors.
The animal tumor models involve metastasis to different organ sites, including the lung, breast, prostate, liver and stomach [22] . In addition, previous cellular studies indicate that tea catechins, especially the most abundant and biologically active EGCG, enhance cancer cell growth suppression and inhibit angiogenesis [25] . Furthermore, the synergistic effects observed in the animal models and cancer cell lines involved multiple molecular mechanisms, such as the induction of growth arrest, DNA damage and the inhibition of receptor-dependent signaling pathways [23] . Numerous anticancer drugs were analyzed in studies of synergy with tea catechins. The following is a review of studies utlizing some of the anticancer drugs.
Paclitaxel
Paclitaxel is a microtubule-targeted drug commonly used for cancer treatment.
However, resistance to paclitaxel is frequently encountered in the clinic [26] . Using paclitaxel displayed no significant changes in weight, suggesting no overt systemic toxicity. Moreover, systematic examination of the major organs, including liver, spleen, heart and kidneys, revealed no histological changes indicative of drug toxicity [27] .
The mechanism of synergistic inhibition of tumor growth by EGCE and paclitaxel involves modulation of chemo-resistance related proteins. It has been reported that EGCG binds to glucose-regulated protein 78 (GRP78), which is over-expressed in chemo-resistant cancer cells [28] . After co-treatment with EGCG and paclitaxel, the expression of GRP78 in tumor tissues were reduced compared with the paclitaxel-treated tumors, indicating that EGCG can overcome paclitaxel-induced GRP78 expression [27, 29] . Thus, EGCG could be used as a sensitizer of paclitaxel cytotoxicity.
Stearns and Wang examined the efficacy of EGCG in combination with taxane (paclitaxel and docetaxel) in a xenograft mouse model of human prostate cancer [30] .
Single-cell suspensions of the human prostate cancer cell line PC-3ML (1 × 10 6 cells) from less than 10 passages were i.p. injected in 5-to 6-week-old CB17 SCID mice.
After approximately 1 week, the drug in a volume of 0.50 ml/mouse was i.p. injected weekly using a 28-gauge needle for 9 weeks. Compared with the control group, the tumor volumes significantly decreased in EGCG and/or paclitaxel treated groups after 1-9 weeks. EGCG (200 μM, 228 mg/kg) plus paclitaxel (20 mg/kg) synergistically inhibited human prostate PC-3ML tumor cell growth. Similarly, no synergistic or additive toxicity characterized by increased body weight was observed. More importantly, the combination therapy inhibited bone metastases after intravenous injection of the PC-3ML cells through the tail vein [30] .
Mechanistically, it was hypothesized that EGCG synergizes with paclitaxel by increasing the expression of apoptotic genes to induce tumor cell apoptosis. In this study, freshly established PC-3ML tumors (i.e., 2 weeks after i.p. inoculation of mice) typically express minimal or no p53, p73, and p21 protein. However, after mice were treated with daily i.p. injections of EGCG or paclitaxel, the expression of p53 and p73 increased more than one-and three-fold, respectively. In comparison, EGCG plus paclitaxel treatment for 2 and 4 days caused the levels of p53, p73, and p21 to increase by more than 5-to 10-fold, respectively. These data suggest that the combination therapy significantly increased the expression of apoptotic genes [30] . In sum, EGCG used in combination with paclitaxel could offer a curative therapeutic approach for the eradication of primary tumors and metastatic prostate cancer. The mechanism(s) governing the synergistic activities of EGCG and paclitaxel require further investigation.
Docetaxel
Docetaxel is a well-established anti-mitotic chemotherapy drug that induces a mitotic block. It displays a broad range of anticancer effects in a variety of cancers, including breast, ovarian, colorectal, prostate, lung, liver, renal, gastric, head and neck, and melanoma [31, 32] . Wu and co-workers reported that docetaxel in combination with EGCG inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts [33] . The volume of the tumors in the combination group was significantly reduced compared with the other groups, suggesting that the combination therapy of LDM docetaxel and EGCG remarkably delays the tumor growth [33] . However, the exact mechanisms governing the interaction between LDM docetaxel and EGCG remain unclear and require further study.
Erlotinib
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has demonstrated strong antitumor and chemopreventive effects through blockade EGFR-related signal transduction pathways in a variety of cancer types [34] .
Zhang and co-workers reported the synergistic inhibition of head and neck tumor growth by green tea EGCG and EGFR-TKI [35] . In this study, the nude mice (athymic nu/nu) were randomly divided into 4 treatment groups: vehicle control (1% Tween 80), EGCG, erlotinib or the combination of EGCG (125 mg/kg) and erlotinib (50 mg/kg). Each group received treatment by oral gavage for 7 days prior to the inoculation of 2 × 10 6 Tu212 cells by s.c. injection into the right flank. The animals were continuously administered the agents 5 days a week after tumor cell injection.
Single agent EGCG or erlotinib moderately inhibited tumor growth, but the results
were not statistically significant compared with the control (p=0.14 and p=0.07, respectively). In contrast, the combination of erlotinib and EGCG suppressed tumor growth compared with the control (p=0.006), single agent EGCG (p=0.02) and single agent erlotinib treatment groups (p=0.01). In addition, the combination group did not achieve a tumor size of 500 mm 3 , whereas the control, erlotinib alone, and EGCG alone groups achieved this size at 19.5, 27, and 25 days, respectively. Furthermore, the combined treatment yielded significantly reduced mean pEGFR levels compared with the control group based on analysis of the proteins extracted from the xenograft tumor tissues. These results suggest that EGCG combined with erlotinib exhibit synergistic antitumor activity with no significant side effects [35] . EGCG and the three additional green tea catechins, in NSCLC patients [37] .
Celecoxib
Celecoxib is a selective inhibitor of cyclooxygenase-2 (COX-2), which has been implicated in the pathogenesis of many cancer types [38] . Huang and co-workers discovered a new treatment strategy for urothelial carcinoma [39] . They found that celecoxib induces cell cycle G1 arrest, endoplasmic reticulum stress, and subsequent apoptosis in human UC cells. Co-treatment with celecoxib and EGCG reduces the expression of GRP78 and enhances celecoxib-induced apoptosis [39] . The mice were sacrificed 33 days after drug administration, and the tumors were resected to measure the intracellular accumulation of DOX, assess P-gp levels, and detect MDR1 mRNA expression [43] . The results showed that administration of DOX in combination with EGCG markedly enhanced intracellular DOX accumulation.
Moreover, EGCG increased topo II expression and significantly reduced the MDR1
and HIF-1· mRNA expression in the tumor xenografts [43] . The study further Cardiac injury is the most serious adverse complication of the oxidative stress-generating DOX [45] . On the other hand, EGCG has been reported to possess a cardioprotective role in diseases associated with oxidative stress [46] . Therefore,
Li et al. investigated whether EGCG protected against DOX-induced toxicity in
cardiomyocytes [47] . The results suggested that EGCG protected cardiomyocytes from DOX-induced oxidative stress by attenuating reactive oxygen species (ROS) production and apoptosis as well as increasing the activity and expression of endogenous antioxidant enzymes (such as manganese superoxide dismutase, catalase, and glutathione peroxidase) [47] .
Cisplatin
Cisplatin, the first member of a class of platinum-containing anticancer drugs, can bind to and crosslink DNA, triggering tumor cell apoptosis. It is used to treat a variety of cancers, including sarcomas, carcinomas such as small cell lung cancer and ovarian cancer, lymphomas, and germ cell tumors [48] . Lee vorinostat [51, 52] , SU-5416 [53] , tamoxifen [54] , daunorubicin [55] , ATO [56] , and etoposide [28] . However, whether these drugs have synergistic effects with tea catechins in animal models has yet to be determined.
Pharmacokinetic interactions
Based on two characteristics of anticancer drugs, their inherent toxicity and narrow therapeutic index, administration of these agents with green tea may cause minor changes in the drug's pharmacokinetics, potentially significantly altering the drug's efficacy or toxicity [57] . The catechins found in green tea may affect the expression or activities of drug-metabolizing enzymes and drug transporters [1] . During a chemotherapeutic regimen, the pharmacokinetics and bioavailability of a chemotherapy may be altered in cancer patients who drink tea. Therefore, studies on the pharmacokinetic interactions of tea catechins with anticancer drugs cannot be ignored.
5-Fluorouracil (5-FU)
5-Fu is an antimetabolite drug that is extensively used for the treatment of cancers, including aerodigestive tract, breast and head and neck cancers. The cytotoxicity of 5-FU is exerted through its inhibition of thymidylate synthase and the incorporation of its metabolites into RNA and DNA, resulting in lethal DNA damage [58] . In our previous study, we reported that green tea extracts increase the bioavailability of 5-FU in rats [59] . After orally receiving 50 mg/kg green tea extract daily for 28 days, the These results suggest that the bile efflux transport system of CPT-11 may be markedly reduced upon treatment with EGCG, a P-gp inhibitor. Moreover, the half-life of CPT-11 could be significantly reduced in hepatobiliary excretion and thereby substantially prolonged in the plasma. Therefore, warnings regarding the pharmacokinetic interaction of CPT-11 and EGCG should be provided to patients, especially those who consume green tea [61] .
Tamoxifen
Tamoxifen and its active metabolite hydroxytamoxifen are antagonists of the estrogen receptor in breast tissue. It is the standard of care endocrine (anti-estrogen) therapy for hormone receptor-positive breast cancer in pre-menopausal women [62] .
Shin and Choi investigated the effects of EGCG on the oral bioavailability and pharmacokinetics of tamoxifen and 4-hydroxytamoxifen in rats [63] . carcinoma to down-regulate P-gp and breast cancer resistant protein (BCRP) [63] .
Bortezomib
On the other hand, tea catechins may have the potential to negate the therapeutic efficacy of a chemotherapy. Bortezomib (BZM) is a proteasome inhibitor clinically used for multiple myeloma [64, 65] . Golden et al. investigated whether the combination of these compounds would enhance antitumor efficacy in multiple myeloma and glioblastoma cell lines in vivo [66] . Unexpectedly, they discovered that various green tea constituents, in particular EGCG and other polyphenols with could not induce endoplasmic reticulum stress, caspase-7 activation, or tumor cell death. Therefore, green tea polyphenols might have the potential to negate the therapeutic efficacy of BZM. The consumption of green tea products might be contraindicated during BZM cancer therapy [66] .
Sunitinib
Another example of a chemotherapy that negatively interacts with EGCG is sunitinib, a novel, oral multi-targeted tyrosine kinase inhibitor for patients with metastatic renal cell carcinoma (mRCC) and advanced gastrointestinal stromal tumor [67] . Ge et al. initially found that drinking tea could interfere with symptom control in an mRCC patient receiving sunitinib [68] . Therefore, they hypothesized that green tea or its components might be antagonistic to sunitinib. Subsequently, a study on the interactions of EGCG and sunitinib was performed in vitro and in vivo. The EGCG and the sunitinib solutions were both clear. However, the solutions became turbid immediately upon mixing and formed an orange precipitate. In addition, the AUC and C max of plasma sunitinib were markedly reduced after co-administration of EGCG and sunitinib to rats, implying that EGCG reduced the bioavailability of sunitinib. A precipitate formed, and sticky, semisolid contents were found in the stomachs of the mice [68] .
Conclusions
Natural compounds have been combined with anticancer drugs to enhance the efficacy of cancer therapies and prevent the acquisition of resistance to the therapies [24, 57, 69] . In this article, we outline the pharmacodynamic and pharmacokinetic interactions between tea catechins and anticancer drugs. Examples are provided to demonstrate the broad range of effects that tea catechins have on anticancer drugs via a variety of mechanisms, such as modulations in the levels of drug-metabolizing enzymes, alterations in the activities of drug transporters and direct binding to drugs.
However, clinical studies in this area are still limited, and future clinical observations on the interaction between tea catechins and anticancer drugs are needed.
Conflict of interest
The authors declare that they have no competing interests. 
